Citations

Clear

861 citation(s) found for "Sd, Wexner".

Technical and clinical success after venous sinus stenting for treatment of idiopathic intracranial hypertension using a novel guide catheter for access: Case series and initial multi-center experience
Zyck, Stephanie , Malik, Muhammad Imran , Webb, Matthew J., Mohammed, Marwa, Powers, Ciarán J. , Birnbaum, Lee , Hawk, Harris, Brinjikji, Waleed , Nimjee, Shahid M. , Malik, Muhammad, Nimjee, Shahid M , Malik, Muhammad, Webb, Matthew, Mohammed, Marwa

Mayo Clinic

Interventional Neuroradiology | November 18, 2022 | Volume: 30 | Issue: 4 | Pages: 524-528

10.1177/15910199221139545 | PMID 36397725 Get It

Introduction Venous sinus stenting is a well established alternative to cerebrospinal fluid diversion for the treatment of idiopathic intracranial hypertension (IIH) with associated venous sinus stenosis. During this procedure, distal guide catheter placement within the venous sinuses may be desirable to facilitate stent delivery. We report our initial experience using the TracStar LDP™ (Imperative Care, Campbell, USA, 0.088-inch inner diameter) as the guide catheter for intracranial access during venous sinus stenting. Methods A multi-institutional retrospective chart review of a prospectively maintained IRB-approved database was performed. Consecutive patients who underwent venous sinus stenting from 1/1/2020-9/6/2021 for IIH were included. Patient characteristics, procedural details, TracStar distal reach, outcomes, and complications were collected and analyzed. Results Fifty-eight patients were included. The mean age was 33.8 years and 93.1% of patients were female. Visual changes prompted evaluation in 86.2% of patients. Stent placement was successful in all patients. The TracStar LDP catheter was advanced to the location of stent placement in 97.9% of cases in which it was attempted. The large 0.088-inch inner diameter lumen enabled compatibility with all desired stent sizes ranging from six to 10 millimeters. Gradient pressure across transverse sinus stenosis dropped from an average of 19.5 mmHg pre-procedure to 1.7 mmHg post-stent placement (p < 0.001). Clinical improvement was achieved in 87.9% (51/58) of patients. There were no catheter-related complications. Conclusion The TracStar LDP is a safe and effective access platform for reaching treatment locations in patients who present with idiopathic intracranial hypertension and who are candidates for venous sinus stent placement.
Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study
Hart, Phil A. , Li, Liang , Yang, Yunlong, Chang, Eleanor, Bellin, Melena D. , Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E., Park, Walter G. , Vege, Santhi Swaroop , Andersen, Dana K. , Conwell, Darwin L. , Yadav, Dhiraj , Goodarzi, Mark O. , Bellin, Melena D , Yadav, Dhiraj , Goodarzi, Mark O , Jeon, Christie Y. , Van Den Eeden, Stephen K , Serrano, José , Whitcomb, David C. , Conwell, Darwin L.

Mayo Clinic

Diabetes Care | November 16, 2022 | Volume: 46 | Issue: 1 | Pages: 46-55

10.2337/dc22-1414 | PMID 36382801 Get It

OBJECTIVE Diabetes that arises from chronic pancreatitis (CP) is associated with increased morbidity and mortality. Methods to predict which patients with CP are at greatest risk for diabetes are urgently needed. We aimed to examine independent risk factors for diabetes in a large cohort of patients with CP. RESEARCH DESIGN AND METHODS This cross-sectional study comprised 645 individuals with CP enrolled in the PROCEED study, of whom 276 had diabetes. We conducted univariable and multivariable regression analyses of potential risk factors for diabetes. Model performance was assessed by area under the receiver operating characteristic curve (AUROC) analysis, and accuracy was evaluated by cross validation. Exploratory analyses were stratified according to the timing of development of diabetes relative to the diagnosis of pancreatitis. RESULTS Independent correlates of diabetes in CP included risk factors for type 2 diabetes (older age, overweight/obese status, male sex, non-White race, tobacco use) as well as pancreatic disease–related factors (history of acute pancreatitis complications, nonalcoholic etiology of CP, exocrine pancreatic dysfunction, pancreatic calcification, pancreatic atrophy) (AUROC 0.745). Type 2 diabetes risk factors were predominant for diabetes occurring before pancreatitis, and pancreatic disease–related factors were predominant for diabetes occurring after pancreatitis. CONCLUSIONS Multiple factors are associated with diabetes in CP, including canonical risk factors for type 2 diabetes and features associated with pancreatitis severity. This study lays the groundwork for the future development of models integrating clinical and nonclinical data to identify patients with CP at risk for diabetes and identifies modifiable risk factors (obesity, smoking) on which to focus for diabetes prevention.
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL
Ashkan, Keyoumars, Campian, Jian , Trusheim, John, Tran, David , Anstass, George, Cobbs, Charles , Heth, Jason , Salacz, Michael, D’Andre, Stacy D. , Aiken, Robert, Moshel, Yaron A., Nam, Jooyeon, Pillainayagam, Clement, Wagner, Stephanie A., Walter, Kevin A. , Chaudary, Rekha, Goldlust, Samuel , Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin O. , Mikkelsen, Tom , Walbert, Tobias , Abram, Steve, Ewend, Matthew G., Khagi, Simon , Lovick, Darren, Kim, Lyndon, Loudon, William G. , Martinez, Nina , Thompson, Reid, Avigan, David , Fink, Karen, Geoffroy, Francois J., Giglio, Pierre , Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott , Nadji‐Ohl, Minou , Sanchin, Lhagva, Sloan, Andrew, Bosch, Marnix L. , Liau, Linda M. , Brem, Steven , IWAMOTO, FABIO MASSAITI , Tran, David D. , Lee, Ian , Bota, Daniela A. , Brenner, Andrew Jacob , Portnow, Jana , Lutzky, Jose , Meisel, Hans Jörg

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii66-vii66

10.1093/neuonc/noac209.259 Get It

Abstract BACKGROUND Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years. We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and METHODS Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo. Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo. The primary and secondary endpoints compare overall survival (OS) with contemporaneous, matched external controls. Four sets of analyses were conducted to ensure rigorous matching of the controls, reduce biases, and confirm the robustness of the results. RESULTS 331 patients were enrolled. With the crossover, 89% received murcidencel. Median OS (mOS) for nGBM patients (n = 232) was 19.3 months from randomization (22.4 months from surgery) with murcidencel vs. 16.5 months from randomization in the controls (HR = 0.80, p = 0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For rGBM (n = 64), mOS was 13.2 months from relapse vs. 7.8 months in the controls (HR = 0.58, p &lt; 0.001). Survival at 24 months post-recurrence was 20.7% vs. 9.6%, and at 30 months post-recurrence was 11.1% vs 5.1%. In nGBM patients with methylated MGMT (n = 90), mOS was 30.2 months from randomization (33 months from surgery) with murcidencel vs. 21.3 months from randomization in the controls (HR = 0.74, p = 0.027). The treatment was well tolerated, with only 5 serious adverse events deemed at least possibly related to the vaccine. CONCLUSION Clinically meaningful and statistically significant survival extension was seen in both nGBM and rGBM patients treated with murcidencel and SOC compared with contemporaneous, matched external controls who received SOC alone.
RADT-07. RADIOGRAPHIC “NECROSIS" FOLLOWING SINGLE-FRACTION SRS AND IMMUNE CHECKPOINT INHIBITION IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH BRAIN METASTASES: AN INTERNATIONAL MULTICENTER STUDY
Ahluwalia, Manmeet S. , Gurewitz, Jason , Bernstein, Kenneth , Wei, Zhishuo , Niranjan, Ajay , Lunsford, L. Dade , Fakhoury, Kareem , Rusthoven, Chad G. , Trudel, Claire, Malouff, Timothy D. , Ruiz-Garcia, Henry, Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Patel, Samir H. , Deibert, Christopher, Prasad, Rahul N. , Raval, Raju R. , Lee, Cheng‐Chia , Green, Sheryl , Sheehan, Jason , Ahluwalia, Manmeet S , Lehrer, Eric J. , Kondziolka, Douglas , Mathieu, David , Bonney, Phillip A. , Picozzi, Piero , Franzini, Andrea , Attuati, Luca , Palmer, Joshua D. , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii50-vii50

10.1093/neuonc/noac209.197 Get It

Abstract OBJECTIVE Immune checkpoint inhibitors (ICI) and stereotactic radiosurgery (SRS) are commonly utilized in the management of brain metastases. Treatment-related imaging changes (TRIC) are a frequently observed clinical manifestation and are commonly classified as radiographic radiation necrosis. However, these findings are not well characterized and may predict for response to SRS and ICI. METHODS The diagnosis-specific graded prognostic assessment was used to guide variable selection. TRIC were determined based upon MRI, PET/CT, or MR spectroscopy and a consensus by local clinical providers was required. RESULTS The analysis included 697 patients with 4,536 brain metastases across 11 institutions in 4 countries. The median follow-up after SRS was 13.6 months. The median age was 66 years, 54.1% of patients were male, and 57.3%, 36.3%, and 6.4% were non-small cell lung cancer, melanoma, and renal cell carcinoma (RCC) histology, respectively. TRIC were observed in 9.8%. On univariable analysis, Karnofsky Performance Status (KPS) (hazard ratio [HR]: 0.98; p &lt; 0.001), presence of TRIC (HR: 0.67; p = 0.03), female sex (HR: 0.67; p &lt; 0.001), and prior resection (HR: 0.60; p = 0.03) were associated with improved OS. On multivariable analysis, KPS (HR: 0.98; p &lt; 0.001) and the presence of TRIC (HR: 0.66; p = 0.03) were associated with improved OS. A V12 Gy ≥ 10 cm3 (Odds Ratio [OR]: 2.78; p &lt; 0.001), prior whole brain radiation therapy (OR: 3.46; p = 0.006), and RCC histology (OR: 3.10; p = 0.01) were associated with an increased probability of developing TRIC. The median OS in patients with and without TRIC was 29.0 and 23.1 months, respectively (log-rank p = 0.03). CONCLUSION TRIC following ICI and SRS are associated with a median OS benefit of approximately 6 months. Further prospective study is warranted to further elucidate the role and etiology of this common clinical scenario.
NIMG-40. RAPID EARLY PROGRESSION (REP) OF GLIOBLASTOMA IS AN INDEPENDENT NEGATIVE PROGNOSTIC FACTOR: RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS
Villanueva‐Meyer, Javier , Hamer, Philip Witt De, Quiñones‐Hinojosa, Alfredo , Borst, Gerben, Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , D’Urso, Pietro Ivo , Trifiletti, Daniel M. , Wesseling, Pieter

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii172-vii172

10.1093/neuonc/noac209.658 Get It

Abstract INTRODUCTION In patients with newly-diagnosed glioblastoma, rapid early progression (REP) refers to tumour regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis appraised published data on REP to better characterise and understand it. METHODS Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to 21/10/21. Studies describing the incidence of REP – tumour growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly-diagnosed glioblastoma, were included. The primary outcome was REP incidence. RESULTS From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0-58.8 years). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1-1.5). The median number of days between MRI scans was 34 days (IQR 18-45 days). The mean incidence rate of REP was 45.9% (range 19.3%-72.0%) and significantly lower in studies employing functional imaging to define REP (p&lt; 0.001). REP/non-REP groups were comparable with respect to age (p=0.99), gender (p=0.33) and time between scans (p=0.81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30-2.43, p&lt; 0.001), shortened progression-free survival (HR 1.78, 95% CI 1.30-2.43, p&lt; 0.001), subtotal resection (OR 6.96, 95% CI 4-51-10.73, p&lt; 0.001) and IDH wildtype versus mutant tumours (OR 0.20, 95% CI 0.02-0.38, p=0.03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72-2.28, p=0.39). CONCLUSIONS REP occurs in almost half of patients with newly-diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
INNV-07. TUMOR TREATING FIELDS (TTFIELDS; 200 KHZ) POST-MARKETING SAFETY DATA FROM PATIENTS WITH GLIOBLASTOMA TREATED BETWEEN 2011–2022
Mrugała, Maciej M. , Lukas, Rimas V. , Glas, Martin , Shi, Wenyin , IWAMOTO, FABIO MASSAITI , Palmer, Joshua D. , Suh, John H.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii142-vii142

10.1093/neuonc/noac209.547 Get It

Abstract Tumor Treating Fields therapy (TTFields; 200 kHz) is a noninvasive, locoregional, antimitotic treatment approved for newly diagnosed glioblastoma (ndGBM), recurrent (r) GBM, malignant pleural mesothelioma, and is being investigated in additional solid tumors. Approval in GBM was based on results of the phase 3 EF-11 (TTFields monotherapy; rGBM) and EF-14 (TTFields therapy/maintenance temozolomide; ndGBM), which showed clinical benefit without an increase in adverse events (AEs). Here we review post-marketing surveillance (PMS) data from patients with brain tumors who received TTFields therapy over an 11-year period. Unsolicited PMS data from patients with brain tumors who received TTFields therapy between October 2011 and March 2022, were included. Overall 23,822 patients were included in this analysis. Most patients (72%) were from North America; 24% from Europe, Middle East and Africa, and 4% from Japan. Birth year was available for 23,784 patients; of these, the average age at treatment start was 57 years (range: 3–103). Diagnoses were ndGBM (67%), rGBM (27%), astrocytoma (WHO grade 3; 4%) and other (2%). Overall, 71% of patients reported ≥ 1 AE, with the most common being skin reaction (42%), electric (tingling) sensation (14%), heat (warmth) sensation (12%), and seizure (11%). Furthermore, 56% of patients reported AEs possibly related to TTFields therapy, with the most frequently reported being skin reaction (42%), electric sensation (14%) and heat sensation (12%), occurring underneath the arrays. Numbers and types of AEs were comparable between age and diagnosis groups. PMS data from &gt; 23,000 patients with brain tumors show that TTFields therapy (200 kHz) is well-tolerated, consistent with the known safety profile; no new safety signals were identified. TTFields therapy is not associated with systemic toxicity; most common possibly-related AEs are localized dermatologic events that can be managed with appropriate prophylaxis and treatment strategies.
Dichotomous role of integrin‐β5 in lung endothelial cells
Blanchard, Neil P. , Link, Patrick A. , Farkas, Daniela , Harmon, Brennan , Hudson, Jaylen, Bogamuwa, Srimathi, Piper, Bryce , Authelet, Kayla , Cool, Carlyne D. , Farkas, László , Farkas, Laszlo , Link, Patrick A , Heise, Rebecca L. , Freishtat, Robert J.

Mayo Clinic

Pulmonary Circulation | November 9, 2022 | Volume: 12 | Issue: 4 | Pages: No page available

10.1002/pul2.12156 | PMID 36438452 Get It

AbstractPulmonary arterial hypertension (PAH) is a progressive, devastating disease, and its main histological manifestation is an occlusive pulmonary arteriopathy. One important functional component of PAH is aberrant endothelial cell (EC) function including apoptosis‐resistance, unchecked proliferation, and impaired migration. The mechanisms leading to and maintaining physiologic and aberrant EC function are not fully understood. Here, we tested the hypothesis that in PAH, ECs have increased expression of the transmembrane protein integrin‐β5, which contributes to migration and survival under physiologic and pathological conditions, but also to endothelial‐to‐mesenchymal transition (EnMT). We found that elevated integrin‐β5 expression in pulmonary artery lesions and lung tissue from PAH patients and rats with PH induced by chronic hypoxia and injection of CD117+ rat lung EC clones. These EC clones exhibited elevated expression of integrin‐β5 and its heterodimerization partner integrin‐αν and showed accelerated barrier formation. Inhibition of integrin‐ανβ5 in vitro partially blocked transforming growth factor (TGF)‐β1‐induced EnMT gene expression in rat lung control ECs and less in rat lung EC clones and human lung microvascular ECs. Inhibition of integrin‐ανβ5 promoted endothelial dysfunction as shown by reduced migration in a scratch assay and increased apoptosis in synergism with TGF‐β1. In vivo, blocking of integrin‐ανβ5 exaggerated PH induced by chronic hypoxia and CD117+ EC clones in rats. In summary, we found a role for integrin‐ανβ5 in lung endothelial survival and migration, but also a partial contribution to TGF‐β1‐induced EnMT gene expression. Our results suggest that integrin‐ανβ5 is required for physiologic function of ECs and lung vascular homeostasis.
660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen
Liao, Chih‐Yi , Henick, Brian S. , Overman, Michael J. , Polite, Blasé N. , Roychowdhury, Sameek , Ahn, Daniel H. , Johnson, Melissa M., Schenk, Desiree, Bae, Kyounghwa, Jooss, Karin , Johnson, Benny , Spira, Alexander I. , Carbone, David Paul , Mahipal, Amit , Johnson, Melissa, Davis, Matthew M. , Ferguson, Andrew, Solomon, Benjamin

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A691-A691

10.1136/jitc-2022-sitc2022.0660 Get It

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Bakouny, Ziad , Grover, Punita , Hsu, Chih–Yuan , Alimohamed, Saif, Bilen, Mehmet Asım , Castellano, Cecilia A. , Desai, Aakash , Elkrief, Arielle , Eton, Omar , Fecher, Leslie A. , Flora, Daniel , Galsky, Matthew D. , Gesenhues, Alicia, Glover, Michael , Gopalakrishnan, Dharmesh , Gupta, Shilpa , Hayes‐Lattin, Brandon , Hendawi, Mohamed , Hsu, Emily , Jandarov, Roman , Jani, Chinmay , Johnson, Douglas B. , Khan, Hina, Khan, Shaheer , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Matar, Sara , McKay, Rana R. , Mishra, Sanjay , Moria, Feras A., Nizam, Amanda , Nock, Nora L. , Nonato, Taylor K., Panasci, Justin , Pomerantz, Lauren , Portuguese, Andrew J. , Provenzano, Destie , Puc, Matthew , Rao, Yuan James , Rhodes, Terence D., Riely, Gregory J. , Ripp, Jacob , Rivera, Andrea Verghese, Shah, Sumit , Shaya, Justin , Subbiah, Suki , Tachiki, Lisa , Valdés-Reyes, Melissa , Weissmann, Lisa B., Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yang, Yuanchu James , Shyr, Yu , Choueiri, Toni K. , Fromowitz, Ariel, Gandhi, Rikin, Gartrell, Benjamin A. , Makower, Della , Sullivan, Darciann O', Ohri, Nitin , Portes, Mary, Verma, Amit , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bitran, Jacob D. , Hallmeyer, Sigrun , Mundt, Daniel , Pandravada, Sasirekha, Papaioannou, Philip V., Patel, Mauli, Streckfuss, Mitrianna, Tadesse, Eyob, Kundranda, Madappa N. , Lammers, Philip E. , Bindal, Poorva , Lam, Barbara C.C., Piper‐Vallillo, Andrew J., Arvanitis, Panos , Klein, Elizabeth J. , Vieira, Kendra, Angevine, Anne H., Bär, Michael, Prete, Salvatore A. Del , Fiebach, Maryann Z., Gulati, Anthony P., Hatton, Edward H., Houston, Kaly, Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Routy, Bertrand , Hoyo-Ulloa, Irma , Dawsey, Scott J. , Lemmon, Christopher A. , Sharifi, Nima , Granada, Carolina , Hoppenot, Claire , Connors, Jean M. , Demetri, George D., Freeman, Dory , Tolaney, Sara M. , Zon, Rebecca L. , Zhang, Tian , Dzimitrowicz, Hannah, Leighton, John, Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Dansoa, Yvonne , Manikowski, Jesse, Vadakara, Joseph , Yossef, Kristena, Beckerman, Jennifer, Goyal, Sharad , Messing, Ian , Steffes, Dawn R., Alsamarai, Susan, Clément, Jessica , Cosin, Jonathan A. , Daher, Ahmad , Dailey, Mark E., Hosmer, Wylie, Jayaraj, Asha, Mather, Jeff, Menendez, Alvaro G. , Nadkarni, Rajani, Serrano, Oscar K. , Yu, Peter Paul , Balanchivadze, Nino, Accordino, Melissa , Bodin, Brianne E, Masson, Cynthia, Alexander, Mariam P., Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Jeffords, Kelly J., Shafer, Danielle , Cárdenas, Ana I, Campos, Rogelio Cuervo, Ramirez, Ana, Gill, David , Lewis, Mark A. , Low, Clarke A., Jones, Michelle M, Mansoor, Abdul-Hai, Mashru, Sandeep H., Werner, Mica A., Cohen, Aaron , Nemecek, Eneida R. , Williamson, Staci, Smith, Stephanie J., Lewis, Grant C., Zaren, Howard A. , Akhtari, Mojtaba, Castillo, Dan R., Cortez, Kimberly, Lau, Eric , Park, Kyu, Reeves, Mark E. , O’Connor, Timothy E. , Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Ramesh, Vidhyalakshmi , Sachs, Zohar , Wilson, Grace, Bardia, Aditya , Gainor, Justin F. , Peppercorn, Jeffrey , Reynolds, Kerry L. , Zubiri, Leyre , Riaz, Irbaz B, Shah, Surbhi, Ayre, Susan K., Bonnen, Mark , Mahadevan, Daruka , McKeown, Cindy, Salazar, Mary, Wang, Chen‐Pin , Bouganim, Nathaniel , Sabbah, Arielle , Tagalakis, Vicky , Nanchal, Rahul , Bahadur, Nadia , Belenkaya, Rimma , Nambiar, Puja H. , Papadopoulos, Esperanza B. , Rosenberg, Jonathan E, Cerrone, Kim, Dill, Jennifer A. , Faller, Bryan A. , Alomar, Mohammed , Hume, Emma C, Islam, Jessica Y. , Ajmera, Archana , Brouha, Sharon S. , Choi, Sharon , Jiang, Jun Yang , Kligerman, Seth , Park, Ji, Bhatt, Padmanabh , Mariano, Melissa G., Thomson, Carey C. , Glace, Mary Grace, Knoble, Jeanna, Zacks, Rosemary, Blau, Sibel , Brown, CarrieAnn, Cantrell, Angela Shaw, Namburi, Swathi, Polimera, Hyma , Rovito, Marc A., Edwin, Natasha, Herz, Katrina, Kennecke, Hagen F. , Monfared, Amelia, Sautter, Rachel R, Cronin, Tara, Elshoury, Amro, Fleissner, Bridget, Hernandez‐Ilizaliturri, Francisco J. , Kariapper, Ariffa, Levine, Ellis , Wicher, Camille P., Misdary, Christian, Shah, Mansi , Batist, Gerald , Cook, Erin , Ferrario, Cristiano , Lau, Susie , Rudski, Lawrence , Dutra, Míriam Santos , Mahmood, Sana , Mico, Vasil, Dixon, Becky, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Jha, Alokkumar , Schapira, Lidia , Lopes, Gilberto , Cardenas, Karen de, Russell, Karen , Stith, Brittany, Taylor, Sharona, Klamerus, Justin F., Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Haynam, Marcy , Jhawar, Sachin R, Karivedu, Vidhya , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Abbasi, Saqib Hussen, Annis, Sandy, Balmaceda, Nicole , Greenland, Steven, Kasi, Anup , Rock, Crosby D. , Luders, Matt, Smits, Melissa, Weiss, Matthias , Chism, David D. , Owenby, Susie, Ang, Celina , Doroshow, Deborah B. , Metzger, Megan , Uyehara, Catherine, Lashley, Latoya N., Sueyoshi, Mark, Patel, Kanishka G. , Riess, Jonathan W. , Borno, Hala T. , Rubinstein, Samuel M. , Ahmad, Syed A. , Brownfield, Lauren, Heilman, Hannah, Kharofa, Jordan , Marcum, Michelle, Sohal, Davendra , Geiger, Christopher L., Russ, Atlantis Dawn, Saker, Haneen , Choi, Horyun, Rho, Young Soo , Feldman, Lawrence , Gantt, Gerald, Hoskins, Kent , Khan, Mahir, Liu, Li , Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Boldt, Anne, Gonzalez, Cyndi J, Su, Chris, Yoon, James J., Bijjula, Ragneel R., Mavromatis, Blanche H., Seletyn, Mildred E., Wood, Barbara R., Kaklamani, Virginia , Beeghly, Alicia, Charles, Lawrence J., Cheng, Alex , Ding, Tan, Enriquez, Kyle T. , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Lewis, Judy T., Reid, Sonya , Saif, Sara, Slosky, David, Solórzano, Carmen C. , Sun, Tianyi , Vega-Luna, Karen, Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Moore, Joan K., Rice, Robert, Cabalona, Wilhelmina D., Cyr, Sandra, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Ravindranathan, Deepak , LoRusso, Patricia , Lustberg, Maryam B. , Masters, Tyler, Verma, Amit , Sachs, Zohar , Choueiri, Toni K , Desai, Aakash P , Bakouny, Ziad , Mishra, Sanjay , Xie, Zhuoer , Zubiri, Leyre , Fiala, Mark A , Bilen, Mehmet A , Portuguese, Andrew J , Lustberg, Maryam , Labaki, Chris , Awosika, Joy A. , Gulati, Shuchi , Bashir, Babar , Berg, Stephanie , Bowles, Daniel W. , Gatti-Mays, Margaret Elena , Hálfdánarson, Þorvarður R. , Hendawi, Mohamed, Hwang, Clara , Joshi, Monika , Knox, Natalie, Ruíz‐García, Erika , Schmidt, Andrew , Schoenfeld, Adam Jacob , Schwartz, Gary K. , Tucker, Matthew D. , Wotman, Michael T. , Thompson, Michael A. , Shah, Dimpy P. , Warner, Jeremy L. , Wise-Draper, Trisha Michel , Goel, Sanjay , Halmos, Balázs , Shapiro, Lauren C. , Shastri, Aditi , Sica, Roberto Alejandro , Henderson, Jeffrey P. , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Gatson, Na Tosha , Loree, Jonathan M. , Lam, Barbara, Peters, Mary Linton B , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Hatton, Edward, Rose, Suzanne J. , Pennell, Nathan A , Painter, Corrie , Li, Ang , Bitterman, Danielle S. , Florez, Narjust , Giordano, Antonio , Morgans, Alicia K. , Nohria, Anju , Saliby, Renée Maria , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Graber, Jerome J. , Hawley, Jessica E. , Loggers, Elizabeth T , Lyman, Gary H , Nakasone, Elizabeth S. , Yeh, Albert C. , Makary, Mina S. , Rosenstein, Lori J. , Elias, Rawad , Fein, Joshua Alexander , Gadgeel, Shirish M. , Bhutani, Divaya , Hershman, Dawn L. , Alexander, Mariam, Reuben, Daniel Y. , De‐la‐Rosa‐Martinez, Daniel , Vilar‐Compte, Diana , McWeeney, Shannon K. , Peters, Solange , Nagaraj, Gayathri , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Rosovsky, Rachel , Bekaii‐Saab, Tanios , Joyner, Michael J. , Senefeld, Jonathon W. , Mesa, Ruben A. , Ramirez, Amelie G , Shah, Pankil , Papenburg, Jesse , Vinh, Donald Cuong , Singh, Harpreet , Bao, Ting , O'Cearbhaill, Roisin E , Philip, John , Robson, Mark E. , Rosenberg, Jonathan E, Wilkins, Cy R. , Tamimi, Rulla M. , Dill, Jennifer, Chandrasekhar, Sanjay Amrith , Cabal, Angelo , Hsiao, Albert , Razavi, Pedram , Reid, Erin G , Rink, Cameron L. , Griffiths, Elizabeth A. , Jain, Prantesh , Moffitt, Melissa , O’Connor, Tracey L. , Smith, Laurie J, Zsíros, Emese , Jabbour, Salma K , Cook, Erin, Miller, Wilson H. , Wilchesky, Machelle , McNair, Christopher M. , Kloecker, Goetz Hans , Khaki, Ali Raza , Nagpal, Seema , Wu, Julie , Whaley, David, Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Berenberg, Jeffrey L. , Fazio, Alyson, Huber, Kathryn E. , Small, Eric J. , Zhang, Sylvia , Andermann, Tessa M. , Jensen, Christopher Edward , Wood, William A. , Latif, Tahir , Shaikh, Hira , Abidi, Maheen Z. , Markham, Merry Jennifer , Acoba, Jared David , Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Zakharia, Yousef , Friese, Christopher R. , Su, Christopher , Zaman, Qamar U, Brown, Alaina J. , Crispens, Marta Ann , Croessmann, Sarah , Davis, Elizabeth J. , Duda, Stephany N. , Hausrath, Daniel J. , Li, Xuanyi , Prescott, Lauren Shore , Wang, Lucy Lu , Aboulafia, David M. , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | November 3, 2022 | Volume: 9 | Issue: 1 | Pages: 128

10.1001/jamaoncol.2022.5357 | PMID 36326731 Get It

ImportanceCytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation.ObjectiveTo determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer.Design, Setting, and ParticipantsThis registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings.ExposuresImmunosuppression due to therapy; systemic anticancer therapy (IO or non-IO).Main Outcomes and MeasuresThe primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications; hospitalized without requiring oxygen; hospitalized and required oxygen; intensive care unit admission and/or mechanical ventilation; death. The secondary outcome was the occurrence of cytokine storm.ResultsThe median age of the entire cohort was 65 years (interquartile range [IQR], 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, and aOR, 0.89; 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33; 95% CI, 1.38-8.01, and aOR, 4.41; 95% CI, 1.71-11.38, respectively). Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79; 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32; 95% CI, 1.42-3.79).Conclusions and RelevanceThis cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm.Trial RegistrationClinicalTrials.gov Identifier: NCT04354701
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis
Klamer, Brett , Brown, Paul D. , Cerhan, Jane H. , Anderson, S. Keith , Carrero, Xiomara W., Whitton, Anthony , Greenspoon, Jeffrey , Ashman, Jonathan B. , Bahary, Jean-Paul , Urbanic, James J., Barker, Fred G., Farace, Elana, Khuntia, Deepak , Buckner, Jan C. , Laack, Nadia N I, Palmer, Joshua D. , Ballman, Karla V. , Parney, Ian F. , Laack, Nadia N. , Hadjipanayis, Costas G. , Giannini, Caterina , Galanis, Evanthia , Roberge, David

Mayo Clinic

JAMA Oncology | October 20, 2022 | Volume: 8 | Issue: 12 | Pages: 1809

10.1001/jamaoncol.2022.5049 | PMID 36264568 Get It

Importance Long-term outcomes of radiotherapy are important in understanding the risks and benefits of therapies for patients with brain metastases. Objective To determine how the use of postoperative whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) is associated with quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors with 1 to 4 brain metastases. Design, Setting, and Participants This secondary analysis of a randomized phase 3 clinical trial included 48 institutions in the US and Canada. Adult patients with 1 resected brain metastases but limited to those with 1 to 4 brain metastasis were eligible. Unresected metastases were treated with SRS. Long-term survivors were defined as evaluable patients who lived longer than 1 year from randomization. Patients were recruited between July 2011 and December 2015, and data were first analyzed in February 2017. For the present study, intracranial tumor control, cognitive deterioration, QOL, and cognitive outcomes were measured in evaluable patients who were alive at 12 months from randomization and reanalyzed in June 2017. Interventions Stereotactic radiosurgery or WBRT. Main Outcomes and Measures Intracranial tumor control, toxic effects, cognitive deterioration, and QOL. Results Fifty-four patients (27 SRS arm, 27 WBRT arm; female to male ratio, 65% vs 35%) were included for analysis with a median follow-up of 23.8 months. Cognitive deterioration was less frequent with SRS (37%-60%) compared with WBRT (75%-91%) at all time points. More patients declined by 2 or more standard deviations (SDs) in 1 or more cognitive tests for WBRT compared with SRS at 3, 6, and 9 months (70% vs 22%, 46% vs 19%, and 50% vs 20%, respectively). A 2 SD decline in at least 2 cognitive tests was associated with worse 12-month QOL in emotional well-being, functional well-being, general, additional concerns, and total scores. Overall QOL and functional independence favored SRS alone for categorical change at all time points. Total intracranial control for SRS alone vs WBRT at 12 months was 40.7% vs 81.5% (difference, −40.7; 95% CI, −68.1% to −13.4%), respectively. Data were first analyzed in February 2017. Conclusions and Relevance The use of SRS alone compared with WBRT resulted in less cognitive deterioration among long-term survivors. The association of late cognitive deterioration with WBRT was clinically meaningful. A significant decline in cognition (2 SD) was associated with overall QOL. However, intracranial tumor control was improved with WBRT. This study provides detailed insight into cognitive function over time in this patient population. Trial Registration ClinicalTrials.gov Identifier: NCT01372774 ; ALLIANCE/CCTG: N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group)